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A report on the European Society of Human Genetics
Conference 2005, Prague, Czech Republic, 7-10 May 2005.
As in previous years, this year’s European Society of Human
Genetics Conference covered a broad and diverse range of
topics in clinical and basic human molecular genetics,
addressing the interests of clinicians, cytogeneticists, molecu-
lar biologists, population geneticists and bioinformaticians.
We will focus here on some of the outstanding presentations
on single-gene and polygenic diseases, high-throughput tech-
nologies and data analysis, the molecular genetics of longevity
and ageing, functions of non-coding DNA, segmental duplica-
tions, and diagnostic tools and development of therapies. 
From single-gene diseases to complex disorders
A number of novel genes involved in the variant pathology of
disorders with known single-gene genetic determinants were
reported. Regina Bendix-Waltes (Hannover Medical School,
Hannover, Germany) reported that a deficiency of the DNA-
repair protein Rad50, as the result of a hypomorphic germline
mutation in the RAD50 gene, caused a variant form of the
Nijmegen breakage syndrome, a disease usually caused by
mutations in another DNA-repair gene and characterized by
chromosomal instability. Anna Benet-Pagès (Institute of
Human Genetics, Munich, Germany) reported a homozygous
missense mutation in the FGF23 gene as the cause of a variant
of familial tumoral calcinosis in which the patient has abnor-
mally low serum phosphate levels rather than the usual ele-
vated serum phosphate. FGF23 encodes a putative circulating
fibroblast growth factor that promotes phosphate excretion.
Anne Goriely (Weatherall Institute of Molecular Medicine,
Oxford, UK) reported that germline mutations in the
fibroblast growth factor receptor 2 gene (FGFR2) that lead to
amino-acid substitutions conferring gain of function are under
positive selection in human spermatogonia. This explains the
high prevalence of paternal de novo mutations leading to
Apert syndrome, which is caused by mutations in FGFR2. 
Discussions on complex disorders - those resulting from
variants in several genes involved in interacting pathways -
focused on recent progress in understanding inflammatory
and immune disorders. Susceptibility to asthma, for
example, depends on variation at an unknown number of
genetic loci. Among the more than 200 significant genetic
associations reported for asthma, less than one third have
been replicated, and those are associated with low relative
risk. Nevertheless, several new genes shown to be associated
with asthma - ADAM33, PHF11, DPP10, DRPR3, and GPRA
- should provide new approaches to understanding impor-
tant aspects of the disease. Juha Kere (Karolinska Institute,
Stockholm, Sweden) described the work of his group on
GPRA, which encodes the G-protein-coupled receptor for
asthma susceptibility, for which no ligand has yet been iden-
tified. A distinct distribution of different isoforms of this
receptor between bronchial biopsies from healthy and asth-
matic individuals has been found; moreover, the analysis of
a 70-kb haplotype block in the GPRA gene in a sample of
children from the Swedish birth cohort study (BAMSE) has
shown an association with sensitization, childhood allergic
asthma and allergic rhinoconjunctivitis.
John Todd (University of Cambridge, UK) reviewed progress
in understanding the genetic basis of type 1 diabetes (insulin-
dependent diabetes) over the past few years. This type of dia-
betes arises from the autoimmune destruction of
insulin-producing beta cells in the pancreas. Five susceptibil-
ity loci for type 1 diabetes have already been identified (HLA
class II genes, the insulin gene (INS),  CTLA4,  CD25 and
PTPN22). About 50 genes have been tested for associationwith the disease, representing a small proportion of the
genes that participate in the disorder, but Todd pointed out
that most reported positive associations are false positives
due to small samples, genotyping problems and population
structure, among other things. The HLA locus is the major
region associated with type 1 diabetes, representing about
40% of familial clustering, with odds ratios of between 4 and
20 (odds ratios indicate an increased likelihood of getting
the disease compared with the general population). Particu-
lar variants of the HLA locus are almost necessary for the
disease, but it is far from sufficient, with a positive predictive
value of about 5%. To identify the other genes involved,
thousands of samples and controls will have to be studied.
The use of the British Birth Cohort collection in gene-associ-
ation studies has identified 8,000 cases of type 1 diabetes,
allowing Todd’s group to confirm the role of CTLA4 in
disease susceptibility, with an allele specific 3 untranslated
region (UTR) giving an odds ratio of 1.24. Todd also
reported the finding that 11% of pediatric cases of type 1 dia-
betes have autoantibodies to the autoimmune thyroid
disease associated antigen thyroid peroxidase, and that the
T-cell immunoregulatory CTLA4 gene is involved in only a
subgroup of patients. 
Genome-wide studies utilizing DNA microarrays to study
single-nucleotide polymorphisms (SNPs) in a large number
of cases and healthy controls have begun, using 10,000-plex
SNP assays produced by Parallele and Affymetrix. The work
has been organized in several phases, starting with 1,000
cases and 1,000 controls. SNPs with minimum allele fre-
quencies of greater than 10% are chosen to begin with, and
the study will then move towards those SNPs showing the
most promising associations. One problem the investigators
have encountered is the peculiar stratification structure of
the British population for several markers, reflecting the
Celtic, Scandinavian and Anglo-Saxon origins of the popula-
tion. In phase I of the study, they also encountered problems
due to the lack of normalization of the DNA samples, so that
the same protocols and the same labs should be mandatory
for these investigations. With regard to the SNPs selected for
analysis, Todd pointed out that Tag SNPs (reference SNPs
for a given genomic region) are still in their infancy, which
means an important loss of potential information from the
current studies. A collaborative Consortium for Cases and
Controls is also being set up in the UK, with support from
the Wellcome Trust, with the aim of studying at least seven
complex disorders in the first round of funding.
Chronic inflammatory disorders such as Crohn’s disease,
eczema, asthma, and psoriasis are triggered by environmen-
tal factors acting on the background of susceptibility genes
with a polygenic action. Stefan Schreiber (Institute for Clini-
cal Molecular Biology, University Hospital of Schleswig-Hol-
stein, Kiel, Germany) reviewed the current knowledge of the
genetics of Crohn’s disease, which is a paradigm for inflam-
matory disorders of the epithelial barriers between the body
and the ‘outside world’. Inflammatory bowel disease (IBD),
of which Crohn’s disease is a form, is one of the complex dis-
orders for which we have gained some basic knowledge
through genetics and genomics. Three disease genes have
been identified for IBD: CARD15 (NOD2),  DLG5 and
OCTNA12. CARD15, a homolog of CARD4 (NOD1), which
is involved in responsiveness to intracellular bacterial
lipopolysaccharides, was the first Crohn’s disease gene to be
identified by positional cloning. Mapping using the two-locus
transmission disequilibrium test (TDT; which detects linkage
of a major trait to a tightly linked marker, thus avoiding the
effect of population stratification in European IBD patients)
identified a disease-associated haplotype block in a sugges-
tive linkage region on chromosome 10q, and has identified
DLG5 in this region as a likely susceptibility gene for IBD. In
contrast to the strong genetic effect of CARD15, where the
associated variant confers a relative risk of disease of more
than 40 for homozygotes and compound heterozygotes, the
risk associated with DLG5 is much smaller (odds ratio of
around 1.5). The mechanism by which variants in the third IBD
susceptibility gene, for OCTNA12, which encodes an organic
cation transporter, contribute to the disease is still unknown.
One interesting hypothesis Schreiber put forward was the idea
that several diseases that are classified as distinct entities, such
as psoriasis, asthma, periodontitis, and sarcoidosis, among
others, could all be included in a general category of inflamma-
tory barrier disorders. The genetic dissection of these diseases
at the phenotypic level and the use of genomic and metage-
nomic approaches should mean rapid progress.
There were several other presentations on polygenic disor-
ders. Emma Banfield (Wellcome Trust Centre for Human
Genetics, Oxford, UK) reported a multivariate linkage analysis
of original data from a whole-genome scan for genetic asso-
ciations with specific language impairment. Using this
approach, she and her colleagues detected three new possi-
ble quantitative trait loci involved in these conditions on
chromosomes 4, 5, and 10, and investigated the relationship
between the phenotypes influenced by the previously identi-
fied loci SLI1 and  SLI2. Silvia Paracchini (University of
Oxford, UK) reported that a previously identified 70 kb risk
haplotype for dyslexia on chromosome 6p22 is associated
with a reduction in transcription of KIAA0319 gene of about
40%. To analyze the allele-specific level of expression of
genes within the candidate region, Paracchini and her col-
leagues tested lymphoblastoid and neuroblastoma cell lines
heterozygous for the risk haplotype on the Sequenom
MassARRAY platform for measuring gene expression. Cisca
Wijmenga (University Medical Center Utrecht, The Nether-
lands) reported novel loci for celiac disease on 6q, 9p and
19p, identified by the sib-pair approach. The 6q locus might
represent a more common autoimmune locus. And finally,
one of us (X.E.) described data from our group on the associ-
ation of anorexia and bulimia with variants in the genes for
brain-derived neurotrophic factor (BDNF) and its receptor
(NTRK2), defining risk and protective haplotypes for
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High-throughput technology and data analysis
On the high-throughput front, a novel array-based whole-
genome genotyping assay that effectively enables unlimited
SNP genotyping from a single sample preparation was
reported by Kevin Gunderson (Illumina, San Diego, USA).
This is accomplished by hybridizing the product of a single-
tube whole-genome amplification reaction to arrays of 50-mer
probes and conducting an array-based allele-specific primer
extension assay. Using Illumina’s bead-based high-density
array platform BeadChip, over 100,000 assays for SNPs
located in exons can be combined on a single chip. Siv
Fokstuen (University Hospital of Geneva, Switzerland)
described the applicability of high-throughput resequencing
for the diagnosis of high-prevalence disorders. The authors
have developed a CustomSeq Resequencing Array (Affymetrix)
with 30,000 probes that enables the rapid molecular diagno-
sis of hypertrophic cardiomyopathy. The array comprises all
coding exons, splice-site junctions and known promoters of 12
genes known to be mutated in the disease; more than 90% of
all mutations reported to date were detected. The complexity
of the data obtained from genome-wide studies has meant the
continual development of new methods for analyzing it. Geral-
dine Clarke (Wellcome Trust Centre for Human Genetics,
Oxford, UK) presented a model-free multipoint method based
on dense sequence-polymorphism data from parent-offspring
trios (two parents and one child) to estimate recombination
rates between adjacent markers. With dense maps of markers
on trios, the effects of linkage disequilibrium and linkage can
be separated, allowing estimation of recombination rates in a
model-free setting which is the basis for the presented multi-
point method.
Salma Kotti and her colleagues (Inserm U535, Villejuif, France)
reported the use of TDT to analyze a suggested interaction
between the HLA-DRB1 and CTLA4 genes that are involved in
predisposition to multiple sclerosis. The effect of each gene was
confirmed, but there was no evidence of any interaction
between them. When the homogeneity transmission test was
applied (that is, the transmission rate of one locus from hetero-
zygous parents is compared between positive or negative for
the other candidate locus) however, a significant difference in
transmission was observed, suggesting an interaction. Kotti
explained this disagreement by showing that, unlike the homo-
geneity transmission test, the TDT (involving two loci) is not
affected by the presence of population stratification. Thus, she
suggested, the homogeneity transmission test may sometimes
lead to a false conclusion of interaction. 
Molecular genetics of longevity and ageing
Identifying genes controlling human longevity is of increas-
ing interest in the light of the general increase in life span in
developed countries. In his talk on methods of identifying
genes for human longevity, Rudi Westendorp (Leiden Uni-
versity Medical Hospital, The Netherlands) suggested that
although 25% of the variation of human life span is
explained by genetic factors, and evolutionarily conserved
mechanisms are prime candidates for influencing longevity,
ageing is under unintended genetic control. There will be
positive selection of haplotypes associated with fertility
rather than longevity, as evolutionary theory predicts that a
genetic predisposition to fertility has effects on survival, and
many animal models for longevity show decreased fertility.
He pointed out that the search for genetic loci that explain
the variability in human longevity has peculiar characteris-
tics. Linkage studies are complicated, as some individuals
are too young to determine their phenotypic status while
others, whose status is defined, have already died. Associa-
tion studies suffer from a lack of equilibrium, as an age-
matched control group is unavailable and use of a younger
control group could introduce a bias towards selection for
fertility over two generations. Westendorp presented two
alternative approaches: investigating linkage in an affected
sib-pair design, and assessment of association in a classic
prospective follow-up study.
Martin Holzenberger (Hôpital Saint-Antoine, Paris, France)
discussed signaling by insulin-like growth factor 1 (IGF-1)
signaling and longevity. The insulin/IGF-1 signaling pathway
has been identified as a major evolutionarily conserved player
in life-span regulation. He described work from his lab
showing that complete suppression of the mouse IGF-1
receptor (IGF-1R) is not compatible with life, but hetero-
zygous knockout IGF-1R+/- mice have a significantly
increased life span, by 33% in females and 16% in males, and
are highly resistant to oxidative stress. IGF-1R+/- mice have
normal energy metabolism, nutrient uptake and physical
activity, and no change is seen in their fertility and reproduc-
tion. Analysis of their rate of growth suggests that significant
changes in response to IGF-1R deficiency occur during short
time periods. Holzenberger also pointed out a link between
aging and longevity and growth hormone signaling. Defi-
ciency of growth hormone in mice leads to a significantly
increased life span associated with reduced fertility or infer-
tility and a reduction in size and weight, suggesting that the
somatotrophin-growth factor pathway is connected to the
regulation of fertility, reproduction and ageing. Both growth
hormone and IGF-1 are promoters of somatic growth and
development; at the level of IGF-1R, however, fertility,
growth and longevity phenotypes dissociate.
A number of genetically determined syndromes can be asso-
ciated with premature or accelerated aging, or progeria.
Nicholas Levy (Faculté de Médecine Timone, Marseille,
France) discussed the involvement of lamins, which are
nuclear proteins of the intermediate filament family in these
syndromes. Alterations in the expression levels, functions
and distribution of lamins A and C characterize a set of
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
http://genomebiology.com/2005/6/9/343                                         Genome Biology 2005, Volume 6, Issue 9, Article 343 Ogorelkova and Estivill  343.3
Genome Biology 2005, 6:343abnormal aging syndromes, including lipodystrophy-atypi-
cal Werner syndromes (LIRLLC and WC), mandibuloacral
dysplasia (MAD), Hutchinson-Gilford progeria syndrome
(HGPS) and restrictive dermopathy (RD). These disorders
range from those with mild effects to those that reduce lifespan
or are even fatal in newborns. Mutations in the LMNA gene,
which encodes both lamin A and lamin C, can be a primary
cause of most of the laminopathies; defects in ZMPSTE24, a
metalloproteinase involved in the processing of lamin A pre-
cursors, can cause MAD and RD. Levy reported that reduc-
tion of dominant-negatively acting unprocessed prelamin A
in vitro and in vivo can reverse the cellular pathological phe-
notype, thus providing the hope of a targeted molecular
therapy. 
Functions of noncoding DNA
Manolis Dermitzakis (The Wellcome Trust Sanger Institute,
Hinxton, UK) presented preliminary results of a whole-
genome association study aimed at identifying functionally
variable regulatory regions that are likely to contribute to
complex phenotypes and disorders. Dermitakis and his col-
leagues have surveyed expression levels for around 700
genes (350 in regions defined by Encyclopedia of DNA Ele-
ments (ENCODE) project, 250 on chromosome 21 and 200
on chromosome 20) in immortalized lymphoblastoid cell
lines from 60 unrelated humans from the Centre d’Etude du
Polymorphism Humain (CEPH) pedigrees, and used the
SNP genotypes of the same individuals, publicly available
from the haplotype-mapping project HapMap, to perform
association analysis. Dermitzakis reported data on 30
ENCODE genes and 120 genes on chromosome 20. Large
numbers of genes with significant inter-individual variation
in expression were identified, and a strong association bias
was found between individual genes and specific SNPs. Both
cis and trans effects on expression variation were found. The
overall cis-effect distance from the target gene can be up to
4 Mb, suggesting that the regulatory landscape may be dif-
ferent from that hypothesized previously.
Ultraconserved elements in the human genome were the
subject of a talk by David Haussler (Howard Hughes Medical
Institute, University of California, Santa Cruz, USA). A com-
parative analysis of human, mouse, rat and chicken genomes
revealed 481 such highly conserved elements of length 200
bp or greater that are totally unchanged in human, mouse
,and rat and have, on average, 96% identity with a species as
distant as the chicken. About half of these sequences overlap
with mRNA-coding sequences, especially those of genes
involved in RNA processing. The remainder neither code for
protein nor appear in the UTRs of known genes, and often
appear in clusters within approximately one Mb regions that
surround genes for transcription factors involved in embry-
onic development. There is experimental evidence that some
of these elements act as distal enhancers located many hun-
dreds of kilobases away from the transcription-factor gene
that they regulate. Haussler presented an experimental func-
tional analysis of POLA/ARX ultraconserved elements that
cluster on the X chromosome. Eight of these most highly
conserved elements in the human genome were tested for
their ability to act as enhancers and for expression of novel
transcripts. Five drive brain-specific expression during mouse
embryonic development, as shown using a β-galactosidase
reporter. The expression pattern of four of these is a subset of
the  aristaless related homeobox (ARX) gene-expression
pattern in the developing mouse brain. Notably, in humans
ARX is associated with spasticity and intellectual disability,
X-linked West syndrome, Partington syndrome, non-syn-
dromic mental retardation and X-linked lissencephaly with
abnormal genitalia. Two of the eight ultraconserved elements
code for small ubiquitously expressed RNAs. Haussler sug-
gested that the ultraconserved elements are likely to have mul-
tiple functions: some acting as nodes of enhancing or
repressing binding sites, others encoding novel functional
RNAs. Other possible functions could be regulation of chro-
matin or higher-order chromosome structures and regula-
tion of mRNA transcripts.
Damian Labuda (Université de Montréal, Canada) discussed
the contribution of gene conversion to genetic diversity. He
described screening for DNA sequence variability in pro-
moter regions, regions arbitrarily defined as 2 kb segments
directly upstream of the first exon, in 40 individuals of
African, Middle-Eastern, European and East-Asian descent.
The variability of the promoter regions was found to be
similar to that of other genomic segments. There was,
however, a great variance in diversity indices among loci,
which might be at least partially due to selection. Of note,
larger than expected average amounts of recombination
were estimated, and this was not only characteristic of pro-
moter regions but was found throughout the genes. The
greater than expected incidence of recombination apparently
reflects gene conversion rather than the presence of recom-
bination hot spots. Labuda suggested that gene conversion,
by disturbing long-range linkage disequilibria and locally
changing the redistribution of functional variants among
haplotypes, may profoundly affect the outcome of linkage
studies and thus disease mapping.
Segmental duplications and large copy-number
variants within the human genome
A hot topic in genomic variability are the large segments of
our genome that have undergone recent evolution and show
variability in their copy number and gene content. Charles
Lee (Brigham and Women’s Hospital, Boston, USA)
reported on the analysis of large-scale copy-number poly-
morphisms in the human genome using array-based com-
parative genomic hybridization (array-CGH). The
microarrays contained probes based on bacterial artificial
chromosome (BAC) human genomic clones spaced at 1 Mb
intervals within the genome. Pairwise analysis of genomic
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identified more than 200 loci that contain large-size copy-
number polymorphisms, some involving hundreds of kilo-
bases of DNA. These loci are scattered throughout the
genome and the polymorphism explains previously observed
locus-specific variation. An average of 12 large-size polymor-
phisms were detected per individual using pooled control
DNA from ten unrelated, healthy individuals. More than
50% of these polymorphic regions overlap known genes and
approximately 25% of the identified loci map to regions pre-
viously thought to contain segmental duplications. Interest-
ingly, some 10% of the loci reside within the 100 kb of gaps
in the current presentation of the human genome. Together,
these large-size copy-number variations may represent as
much as a tenfold greater amount of genetic variation than
SNPs in humans. A searchable database that will provide an
updated catalog of these variations for accurate interpreta-
tion of whole-genome-directed arrayCGH assays in research
and clinical settings has been established
[http://projects.tcag.ca/variation/]. The previously unap-
preciated large-scale genomic heterogeneity argues for a
more dynamic picture of the structure of the human genome.
Further studies are likely to yield evidence as to whether
these regions are associated with disease-linked rearrange-
ments or account for genetic differences in susceptibility to
diseases or reaction to specific environmental stimuli.
Bert De Vries (Human Genetics Nijmegen, Radboud Univer-
sity, Nijmegen, The Netherlands) reported the use of whole-
genome tiling-path array-CGH to detect submicroscopic
chromosome alterations at 100 kb resolution in patients with
mental retardation and/or congenital anomalies. DNA copy-
number alterations were detected in most patients, most vari-
ation being inherited from parents and corresponding to
large-scale copy-number variants of the type described above.
Some patients had de novo alterations - deletions or duplica-
tions - varying in size between 300 kb and 10 Mb. Submicro-
scopic alterations were identified in around 14% of the cases.
Stefan Kirsch (University of Heidelberg, Germany) described
an analysis of interchromosomal segmental duplications of
the pericentromeric region on the human Y chromosome. He
and his colleagues have identified and analyzed a euchromatic
island within the pericentromeric repeats of the human Y
chromosome. This 450 kb island was not detected and is not
contained within the published Y chromosomal sequence. The
entire 450 kb interval is almost completely duplicated and
consists predominantly of interchromosomal duplication
rather than the intrachromosomal duplications that are
usually prevalent on the Y chromosome. The duplicated region
contains eight putative genes with open reading frames,
involving members of the DUX homeobox gene family. 
Diagnostic tools and development of therapies
Mutations in the BRCA1 gene are implicated in an increased
risk of breast and ovarian cancer, and in 2001 the European
Patent Organization (EPO) granted three patents on BRCA1,
in the face of strong opposition from European scientists. Gert
Matthijs (Center of Human Genetics, Catholic University of
Leuven, Belgium) discussed the history of this opposition, and
its successful outcome. The patentees involved the US
company Myriad Genetics, based in Salt Lake City, Utah, and
the University of Utah. The patents gave Myriad Genetics a
monopoly on diagnostic testing of BRCA1 and the right to levy
a license fee, which evoked strong opposition from European
geneticists, supported by several European governments. The
first patent, which claimed “a method for diagnosing the pre-
disposition for breast and ovarian cancer” by comparing the
patient’s  BRCA1 sequence with a reference sequence, was
revoked in May 2004. In January 2005, the two other patents
were maintained in modified form after a final hearing. They
no longer include a method for diagnostics, but only relate to
a probe for BRCA1 and a probe for a common 185delAG
mutation found in Ashkenazi populations, respectively. In
practice, the patents will no longer interfere with breast and
ovarian cancer diagnostics in Europe. The successful attack
was based on errors contained in the DNA sequence as it was
disclosed in the patent application in 1994. The process of
opposing and reconsidering the patents granted by EPO has
been extremely costly for the European community, and
Matthijs suggested that patents should be restricted to tech-
nologies and innovative discoveries that improve diagnostics
and treatment, and that no natural DNA sequences and vari-
ants should be subject to patenting.
Between 40% and 70% of people who receive treatment with
a particular drug do not respond satisfactorily. The adverse
effects of drugs are also a high cost to society, estimated at
several million euros and hundreds of thousands of deaths
every year worldwide. Magnus Ingelman-Sundberg
(Karolinska  Institute, Stockholm, Sweden) reviewed the
variability between individuals in drug action and response.
Variability can arise from the fact that many of the proteins
involved in drug transport and metabolism are polymorphic;
this has both qualitative and quantitative effects, leading, for
example, to the enhancement of drug metabolism and rapid
loss of the drug from the body. Ingelman-Sundberg cited
several examples in which drugs are rendered ineffective as a
result of ultra-rapid metabolism caused by multiple copies of
particular genes or by a high level of allelic variability. The
best current explanation for variability in the copy number
of some genes is related to their selection to respond to
environmental stress. The cytochrome P450 isoenzymes
CYP2C19 and CYP2D6, for example, are involved in the
metabolism of many widely used drugs, and polymorphisms
in these enzymes give rise to inter-individual and inter-
ethnic-group variability in the metabolism of several thera-
peutic drugs, including some antidepressants. People who
carry two null alleles of either gene are known as poor
metabolizers (PMs), while those who carry more than two
copies of a functional CYP2D6 gene are ultrarapid metabolizers
(UMs); UMs are over-represented in the non-responder
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40 million Europeans carry multiple copies of the CYP2D6
gene with differences depending on the geographic location,
this might largely explain the frequent lack of response to anti-
depressants and other drugs in the European population.
Another source of variability in drug response is alternative
splicing of several of the CYP3A genes, which leads to variabil-
ity between individuals from different ethnic backgrounds.
Exploration of copy number, splicing alleles and other specific
variants should facilitate the understanding of the conse-
quences for drug response between and within populations.
Recent advances in human genetics, providing molecular,
biochemical and cellular understanding of diseases have
raised considerable hopes for a better future for patients
with genetic diseases. A stimulating presentation by Arnold
Munnich (Hôpital des Enfants Malades Necker, Paris,
France) showed the range of approaches that can now be
explored to overcome specific molecular defects. These
include protein engineering, enzyme replacement therapy,
rectification of splicing defects, and re-expressing embryonic
genes, as in the successful re-expression of fetal haemoglobin
by hydroxyurea stimulation to treat thalassemias and sickle-
cell anemia. Similarly, Munnich showed that even if it is not
possible to correct or replace the underlying defective gene,
therapeutic strategies based on current knowledge should be
able to ameliorate particular aspects of a disorder. We can
look forward to further progress in this direction at future
year’s European Conferences.
343.6 Genome Biology 2005, Volume 6, Issue 9, Article 343 Ogorelkova and Estivill http://genomebiology.com/2005/6/9/343
Genome Biology 2005, 6:343